News By Tag
News By Location
Follow on Google News
Cmed Technology adds more capabilities to its encapsia platform and reports increased demand for use
Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity.
By: Scott PR
Cmed Technology prioritizes enhancements through alignment of client feedback with strategic and environmental changes to the marketplace (e.g., the pandemic). Our project managers and technical consultants operate collaboratively with the client operational teams, holding regular deep-dive governance meetings to support the goals of our clients at both tactical and strategic level.
As biotechnology, pharmaceutical, and medical device companies resumed clinical development in 2020, the new reality necessitated solutions to make managing, interpreting, visualizing, and analyzing data from their clinical programs simpler. This required augmenting and automating clinical research processes to facilitate these decentralized, virtualized, and hybrid trials. Since Q4 2020, Cmed has seen a rapid uptake of the encapsia platform, particularly eSource, by sponsors conducting everything from phase I to large scale phase IV studies.
Some of the latest encapsia enhancements include:
For more information, please visit https://encapsia.com/